Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan.
Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan.
Arthritis Res Ther. 2018 Jan 11;20(1):7. doi: 10.1186/s13075-017-1506-7.
Interstitial lung disease (ILD) is the principal cause of death in polymyositis/dermatomyositis (PM/DM). Here we investigated prognostic factors for death and serious infection in PM/DM-ILD using the multicenter database.
We retrospectively reviewed baseline demographic, clinical and laboratory findings, treatment regimens and outcomes in patients with PM/DM-ILD. The distribution of ILD lesions was evaluated in four divided lung zones of high-resolution computed tomography images.
Of 116 patients with PM/DM-ILD, 14 died within 6 months from the diagnosis. As independent risk factors for early death, extended ILD lesions in upper lung fields (odds ratio (OR) 8.01, p = 0.016) and hypocapnia (OR 6.85, p = 0.038) were identified. Serious infection was found in 38 patients, including 11 patients who died of respiratory or multiple infections. The independent risk factors were high serum KL-6 (OR 3.68, p = 0.027), high initial dose of prednisolone (PSL) (OR 4.18, p = 0.013), and combination immunosuppressive therapies (OR 5.51, p < 0.001).
The present study shows the progression of ILD at baseline is the most critical for survival and that infection, especially respiratory infection, is an additive prognostic factor under the potent immunosuppressive treatment.
间质性肺病(ILD)是多发性肌炎/皮肌炎(PM/DM)患者的主要死亡原因。在此,我们使用多中心数据库研究了 PM/DM-ILD 患者死亡和严重感染的预后因素。
我们回顾性分析了 116 例 PM/DM-ILD 患者的基线人口统计学、临床和实验室检查、治疗方案和结局。采用高分辨率计算机断层扫描图像将 ILD 病变分为四个肺区进行评估。
在 116 例 PM/DM-ILD 患者中,有 14 例在诊断后 6 个月内死亡。上肺野扩展的 ILD 病变(优势比(OR)8.01,p=0.016)和低碳酸血症(OR 6.85,p=0.038)是早期死亡的独立危险因素。38 例患者发生严重感染,其中 11 例死于呼吸或多发性感染。高血清 KL-6(OR 3.68,p=0.027)、初始泼尼松龙(PSL)剂量高(OR 4.18,p=0.013)和联合免疫抑制治疗(OR 5.51,p<0.001)是独立的危险因素。
本研究表明,基线时 ILD 的进展对生存至关重要,感染,特别是呼吸道感染,是强力免疫抑制治疗下的附加预后因素。